Phillygenin prevents osteoclast differentiation and bone loss by targeting RhoA

Area of Science:

• Pharmacology
• Bone Biology
• Traditional Chinese Medicine

Background:

• Forsythia suspensa tea is a traditional remedy with unclear effects on bone metabolism.
• Osteoclastogenesis is crucial for bone resorption and associated diseases.

Purpose of the Study:

• To investigate the effect and mechanism of Phillygenin (Phi) on bone metabolism.
• To explore Phi's potential in treating bone loss diseases.

Main Methods:

• In vivo (osteolysis and bone loss models) and in vitro studies on osteoclastogenesis.
• Micro-CT, pQCT, TRAP staining, CCK8, TUNEL, BrdU assays.
• RNA sequencing, activity-based protein profiling, molecular docking, G-LISA, and Western blotting to identify mechanisms.

Main Results:

• Phi significantly inhibited bone resorption in vivo and osteoclast formation in vitro.
• Ras homolog gene family member A (RhoA) was identified as the direct target of Phi.
• Phi acts as a RhoA inhibitor, modulating ROCK1, NF-κB/NFATc1/c-fos pathways, and F-actin ring stability.

Conclusions:

• Phillygenin demonstrates anti-osteoclastogenesis and bone-protective effects by targeting RhoA.
• Forsythia suspensa and its compound Phi represent a potential therapeutic strategy for bone loss diseases.